<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178461</url>
  </required_header>
  <id_info>
    <org_study_id>0049-17-MMC</org_study_id>
    <nct_id>NCT03178461</nct_id>
  </id_info>
  <brief_title>The Effect of Warmed Parenteral Fluids During Delivery</brief_title>
  <official_title>The Effect of Warmed Parenteral Fluids During Vaginal Delivery and Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the influence of warm IV fluids during delivery and cesarean section on perinatal
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized controlled trial. Assessing the influence of warmed parenteral fluids
      during delivery/cesarean section on the obstetrical and neonatal outcome. The investigators
      will randomize parturients during the active phase of labor to receive either body
      temperature warmed parenteral fluids or room temperature parenteral fluids. Both groups will
      receive the same fluid composition of 5% dextrose with normal saline. The investigators will
      compare the obstetrical and neonatal outcomes of the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization two 2 groups according to temperature of IV fluids. One group will receive room temperature fluids and the other group will receive body temperature fluids.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of the second stage of labor</measure>
    <time_frame>up to 5 hours from complete cervical dilation</time_frame>
    <description>How much time did it take from complete cervical dilation to the delivery of the baby.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of perineal tears and episiotomies</measure>
    <time_frame>immediately after vaginal birth</time_frame>
    <description>The prevalence of perineal tears and episiotomies that occurred during vaginal delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal APGAR score</measure>
    <time_frame>up to 5 minutes from delivery</time_frame>
    <description>Comparison of the 1 minute and 5 minute APGAR score that the neonates received, between the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of prolonged second stage</measure>
    <time_frame>immediately after completion of the delivery.</time_frame>
    <description>The percentage of patients, in each group, that were defined with a prolonged second stage. The definition is more than 2 hours from complete cervical dilation until delivery of the baby in multipara patients and more than 3 hours from complete cervical dilation until delivery of the baby in nullipara patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7000</enrollment>
  <condition>Delivery, Obstetric</condition>
  <arm_group>
    <arm_group_label>Room temperature parenteral fluids</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will receive IV room temperature fluids, which is the standard of care.
The composition of the fluids given will be normal saline with 5% dextrose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Body temperature parenteral fluids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive IV warmed fluids, body temperature, which is the experimental intervention.
The composition of the fluids given will be normal saline with 5% dextrose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Body temperature parenteral fluids</intervention_name>
    <description>2 study groups shall receive the same parenteral fluids but at different temperatures.</description>
    <arm_group_label>Body temperature parenteral fluids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancies

          -  term pregnancies

          -  receiving parenteral fluids

        Exclusion Criteria:

          -  high order pregnancies

          -  preterm pregnancies (before 37 weeks of gestation)

          -  known fetal major anomaly

          -  known fetal significant chromosomal/genetic abnormality
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only females are pregnant. The baby can be of either sex</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanoch Schreiber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clalit Health Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanoch Schreiber, MD</last_name>
    <phone>972-53-332-3248</phone>
    <email>hanoch.schreiber@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tal Weissbach, MD</last_name>
    <phone>972-546-250-299</phone>
    <email>ferbyt@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanoch Schreiber, MD</last_name>
      <phone>972-53-332-3248</phone>
      <email>hanoch.schreiber@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Yair Daykan, MD</last_name>
      <phone>0542198231</phone>
      <email>yair.daykan@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Hanoch Schreiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanoch Schreiber</last_name>
      <phone>0533323248</phone>
      <email>Hanochsc@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meir Medical Center</investigator_affiliation>
    <investigator_full_name>hanoch schreiber</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Caesarean Section</keyword>
  <keyword>Delivery</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All primary and secondary outcome measures will be made available within 6 months of syudy completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

